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Influence of Natural and Synthetic Estrogens on the 
Course of Autoimmune Disease in the NZB/NZW Mouse 
Sara Ellen Walker and Giles G. Bole, Jr 
Antinuclear antibodies were found in 64% of serum samples obtained 
from male NZB/NZW mice after 6 weeks of treatment with mestranol. Both 
female and male mice responded to this synthetic female hormone with 
marked elevations of serum “2’ and p-globulins; 7-globulins were not in- 
creased. There was no evidence that mestranol accelerated the develop 
ment of autoimmune renal disease in these animals. Treatment of hybrid 
New Zealand mice with mestranol, 17-pestradiol and oophorectomy exerts 
divergent effects on serum proteins and the development of serologic 
abnormalities. 
Systemic lupus erythematosus (SLE) is 
known to have a striking predilection for wom- 
en (1). This observation has stimulated re- 
peated attempts to define the relationship be- 
tween female hormones and autoimmune 
disease. We have previously reported the results 
of treating hybrid New Zealand Black/New 
Zealand White (NZB/NZW) mice (animal 
models of SLE) with 17-p-estradiol (2). Daily 
administration of this naturally-occurring fe- 
male hormone influenced serum globulin con- 
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centrations but had no effect on the early course 
of disease in NZB/NZW mice. Nevertheless, 
recent evidence suggests that exogenous admin- 
istration of compounds containing synthetic es- 
trogens may influence autoimmune phenomena 
in women. Systemic lupus erythematosus may 
exacerbate during treatment with oral con- 
traceptives (3). Kay, Bole and Ledger (4) re- 
ported the appearance of antinuclear antibodies 
(ANA) or rheumatoid factor in the serum of 
women taking synthetic estrogen-progestogen 
compounds. This report describes studies un- 
dertaken to evaluate the influence of a synthetic 
estrogen, mestranol, on the evolution of au- 
toimmune disease in NZB/NZW mice. 
MATERIALS AND METHODS 
Animols. Breeding pairs of NZB and NZW mice were 
initially supplied by Dr. William D. Hall, The University 
of Otago, Dunedin, New Zealand. Each strain is main- 
tained by brother-sister matings. 
Mestrtmol and Estrodiol Studies. Mestranol (the 3- 
methyl ether of ethinyl estradiol)* was obtained through the 
courtesy of G.S. DuBoff, DSC; 17-8-estradiol was pur- 
chased from Mann Research Laboratories. t 
*G.D. Searle Company, Chicago, 111. 
+Division of Becton, Dickinson and Company, New 
York. NY. 
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Littermate female and male mice were assigned at ran- 
dom to treatment or control groups. In the mestranol study, 
29 NZB/NZW mice (18 females and 1 1  males) received 
daily subcutaneous injections of the steroid in a dose of 2.0 
%/kg body weight. This dose is equivalent, on a weight 
basis, to the amount of mestranol ingested daily by a 50-kg 
woman taking an oral contraceptive containing 100 pg of 
the estrogen per tablet. In the estradiol study, 31 NZB/ 
NZW mice (23 females and 8 males) received daily injec- 
tions of 17-&estradiol, 2.5 pg/kg body weight, as previous- 
ly described (2). Twenty-seven control mice were injected 
daily with equivalent volumes of proplyeneglycol vehicle. 
Injections were started when all mice were 4 to 6 weeks old. 
Animals were bled from the orbital plexus before injections 
started anu at 4, 6, 8 and 12 weeks of treatment.. After 8 
weeks, subgroups of control and treated mice were bled at 
4-week intervals. At 12 weeks of treatment, sera were 
available, as noted in Table 3. 
Oophorectomy Study. Ovaries were removed from 2 
groups of NZB/NZW females: a)  Immature: 12 mice, aged 
4 to 6 weeks, were bled before and 6 weeks after surgery. 
Renal tissue was obtained from 1 female that died unex- 
pectedly at 29 weeks of age and from 5 females that were 
sacrificed at 31 to 33 weeks of age. The  evolution of au- 
toimmune disease in these young animals was compared to 
the course of disease in immature control, mestranol- and 
estradiol-treated mice. b) Mature: 12 mice, aged 8 to 12 
weeks. Nine control females 8 to 15 weeks of age had sham 
oophorectomies. T o  assess the long-term effects of gonad 
removal in these older NZB/NZW females, they were bled 
6 and 12 weeks after surgery. Kidneys were examined from 
3 mature oophorectomized females that died of renal in- 
sufficiency at 32 to 33 weeks of age and from 5 females that 
were sacrificed at the age of 43 to 46 weeks. Renal tissue 
was obtained from 4 sham-operated control females. One 
control died at the age of 28 weeks, and 3 controls were 
*In the thirteenth week of mestranol therapy, treated 
females and males began to die. At autopsy, bladder disten- 
tion with hydronephrosis and hydroureters was found. 
Rapid autolysis after death prevented adequate microscopic 
examination of tissues removed at autopsy in most of these 
animals. The  surviving 5 females and 3 males in the group 
treated with mestranol were bled and killed in 2 groups at 
22 and 26 weeks of treatment, and renal and hepatic tissue 
was obtained for histologic study. After 12 weeks of treat- 
ment with estradiol, male mice began to die. These animals 
also had evidence of lower urinary tract obstruction. A high 
incidence of lower urinary tract obstruction and sudden 
death in mice injected with estradiol has been noted by 
other investigators (5). Renal tissue was not recovered from 
these mice. Kidneys and liver from 5 estradiol females 
which were killed after 16 to 20 weeks of treatment were 
available for examination. 
killed at 41 to 48 weeks of age. Tissue was not obtained 
from the other 5 animals in this group due to unanticipated 
deaths and autolysis. 
Antinuclear Antibodies. Serum was stored in capil- 
lary tubes without preservatives at -20" C. Throughout this 
study, positive control sera from 12-month-old NZB/NZW 
females with positive lupus erythematosus cell preparations 
and negative control sera from immature Swiss Webster 
mice were used. When human leukocyte substrate was 
used, great care was exercised to prevent mechaniral 
damage and drying of the cells, which may distort nuclei 
and interfere with the interpretation of positive tests (6). 
All glassware, except microslides, was siliconized. Hepa- 
rinized blood was obtained from a single donor. Erythro- 
cytes were sedimented with 5% glucose and 6% dextran in 
0.15 M NaCl (7). After centrifugation, drops of the leuko- 
cyte-rich plasma supernate were transferred gently to gela- 
tin-coated slides. The  slides were placed in a moist charn- 
ber for 30 minutes to allow the white blood cells to settle. 
These cells were washed gently with phosphate-buffered 
saline (pH 7.0) and fixed in 95% ethanol for 30 minutes. 
Sera obtained from mestranol-treated mice after 4, 6 and 8 
weeks of treatment were also tested on human thyroid tis- 
sue obtained at necropsy from a 5-day-old infant. Sections 
of thyroid tissue, 4 p thick, were prepared on a cryostat 
and fixed in acetone. Samples of mouse serum were applied 
to white blood cell or thyroid substrate, and testing for 
ANA was performed using the indirect immunofluorescent 
procedure described by Friou (8). Fluorescein-con,jugated 
goat antimouse 7.5 y-globulin* diluted 1 :20 was employed. 
Slides were examined without knowledge of the treatment 
status of mice. 
Mestranol. dissolved in propyleneglyrol. was diluted 
with ANA-negative serum from Swiss Webster mire, in 
concentrations ranging from 5.0 x to 2.5 x 10-I" 
mg/ml. T h e  mestranol-serum mixtures and propylenegly- 
col were applied separately to both leukocyte and thyroid 
substrates, and routine tests for ANA were performed. 
Serum Protein Determinations. Electrophoresis of 
mouse serum on cellulose acetate and measurement of total 
serum proteins were preformed as described elsewhere (2). 
Measurement of total y-globulins was cornpared with the 
determination of IqG levels in some animals by radial im- 
munodiffusion (2). 
Histology. Renal and liver tissue fixed in Carnoy's 
solution was embedded in paraffin and 4-8 sections were 
prepared. T h e  tissue sections were stained with hematoxy- 
lin and eosin and examined by light microscopy. Pirani, 
*Immunology, Inc, Glen Ellyn, 111. 
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Table 1. Antinuclear Antibodies (Leukocyte Substrate) in Control and Treated NZB/NZW Mice 
Treatment (wk) 
No. positive tests/total mice tested 









































Pollak and Schwartz (9) described a reproducible se- 
miquantitative method of analyzing abnormal renal mor- 
phology which can be used to assess histologic changes in 
the kidneys of NZB/NZW mice (10). A modification of this 
method was used to examine kidneys from mice in this 
study. An examiner who was not aware of the treatment 
status of the mice counted the number of histologic abnor- 
malities in 20 glomeruli in a section from each kidney 
studied. Lesions counted were: a) thickening or hypercellu- 
larity of the mesangial stalk, b) focal qlomerular hypercel- 
lularity, c) thickening of the basement membrane, d) diffuse 
glomerular hypercellularity, e) fibrinoid change, f) crescent 
formation and g) sclerotic glomeruli. For comparison, a 
number of kidneys from untreated female NZB/NZW 
mice, in our colony, have also been graded using this sys- 
tem. As untreated mice increase in age, there is essentially a 
linear increase in numbers of renal abnormalities. 
Statistical Analysis. Data for the ANA were analyzed 
employinq a x2  formula (1 1). Serum levels of a*-, 8- and 7- 
globulins were analyzed statistically using Cochran’s ap- 
proximation of the Behrens-Fisher test described by 




In Table 1, positive tests detected on leuko- 
cyte substrate in control mice are compared with 
results in NZB/NZW mice treated with mes- 
tranol, 17-&estradiol and oophorectomy. The  
development of ANA was accelerated in young 
NZB/NZW males treated with mestranol. Af- 
ter 6 weeks of treatment, the appearance of 
ANA in 64% of these males compared to ANA 
in 11 70 of male controls was found to be sig- 
nificant by x’ analysis (P  < 0.025). The  ap- 
parent increase in numbers of positive tests in 
mestranol-treated females at 6 weeks and in 
males and females at 12 weeks compared to 
control mice was not significant. 
The  occurrence of serologic abnormalities in 
NZB/NZW mice before and after 6 weeks of 
treatment with estradiol has been described in 
detail elsewhere (2). Antinuclear antibodies in 
estradiol mice are listed in Table 1 to permit 
comparison between mestranol and estradiol 
groups after 6 and 12 weeks of treatment. Posi- 
tive tests for ANA in mestranol females were 
significantly increased at 6 weeks when these 
mice a r e  compared to estradiol females 
(P  < 0.050). Comparison of positive tests in 
treated males shows that a significant number 
of mestranol males, compared to estradiol 
males, were positive for ANA at 6 weeks 
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Table 2. Patterns of Nuclear Fluorescence (Leukocyte Substrate) in NZB/NZW Mice 
Treated with Mestranol 
No. No. of 
of sera positive 
Mice tested tests Peripheral* Homogeneous" Mixed* 
Untreated females 43 13 7 6 0 
Mestranol-treated females 47 21  15 5 1 
Mestranol-treated males 40 28 16 8 4 
*Number of tests 
( P  < 0.005) and 12 weeks ( P  < 0.025). 
As NZB/NZW mice grow older, the inci- 
dence of ANA increases (13). Therefore, in 
Table 1 tests performed in immature castrated 
females are compared with results in young 
female controls (4 to 6 weeks). Older oophorec- 
tomy females (8 to 12 weeks) are compared 
with mature sham-operated controls (8 to 15 
weeks). Oophorectomy failed to influence the 
formation of ANA in either group of mice. 
Eighty-seven samples of sera from mestranol- 
treated female and male mice obtained at 4, 6 , 8  
and 12 weeks of treatment were tested for ANA 
on human leukocyte substrate. Forty-three 
serum samples from untreated NZB/NZW 
females, aged 4 to 16 weeks, were also tested. 
Each positive test demonstrated a homogene- 
ous, peripheral or mixed pattern of nuclear 
immunofluorescent staining. Homogeneous 
staining is illustrated in Figure 1A. Peripheral 
staining (Figure 1 B) was characterized by pale 
nuclear fluorescence with intense staining 
around the periphery of the nucleus (6). Other 
positive sera produced a mixed pattern of 
peripheral or homogeneous staining identified 
in individual nuclei on a single slide. T h e  oc- 
currence of each pattern is listed in Table 2. A 
peripheral pattern was most common in all 3 
groups  of an imals .  T h e  occurrence of a 
peripheral pattern in 16 of 40 sera tested from 
mestranol males is significant when this group 
is compared to control females (P  < 0.025). 
Fig 1. Photomicrographs of patterns of nuclear immunofluorescence in positive tests for ANA. A. 
Homogeneous pattern on human leukocytes (x500). B. Peripheral pattern on human leukocytes 
( ~ 5 0 0 ) .  C. Peripheral pattern on human thyroid (x312). 
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After an unexpectedly large number of posi- 
tive tests for ANA were found in male mes- 
tranol-treated mice initially tested on white 
cells, antinuclear activity was reassessed by re- 
peat testing using both human leukocytes and 
human thyroid as substrate. Undiluted sera 
obtained from 21 mestranol females and males 
bled at 4, 6 and 8 weeks of treatment were di- 
vided into duplicate samples and applied to 
white cells and thyroid slices. As early as 4 
weeks after mestranol therapy began, 8 of the 
11 males in this treatment group had positive 
tests for ANA on leukocytes. Concomitant test- 
ing on thyroid showed that 6 of the 11 samples 
of sera were positive for ANA. The  increased 
frequency of positive tests for ANA initially 
found in mestranol-treated males after 6 weeks 
of treatment (Table 1) was also confirmed by 
testing on thyroid tissue. Fifty-seven percent of 
the sera tested on thyroid at 6 weeks was posi- 
tive. After receiving mestranol injections for 8 
weeks, 7 of the 8 males tested were positive for 
ANA on white blood cells and 6 of these ani- 
mals were positive on thyroid slices. In 1 5  
instances, samples of sera found to be positive 
on white blood cells were negative when tested 
on thyroid. The  most consistent correlation 
between the 2 substrates was found in sera 
from the 8 males that were positive for ANA 
(12 to 14 weeks of age) treated with mestranol 
for 8 weeks. All positive tests on thyroid slices 
showed peripheral staining (Figure lC),  and no 
homogeneous or mixed patterns of immuno- 
fluorescence were found. 
. T o  investigate the stability of patterns in di- 
luted sera, serial dilutions of known positive 
sera from 6 mestranol-treated mice, aged 20 
weeks, were tested on human leukocytes. Sera 
were positive at titers of 1 :64 to 1:128. In 5 in- 
stances, the patterns were unchanged in diluted 
sera (4 homogeneous and 1 peripheral). One 
pattern changed from homogeneous in undi- 
luted serum to peripheral in serum diluted 
serially from 1 :2 to 1 :64. 
Both mestranol and propylene glycol were 
tested for ability to cause fluorescence of 


















Treatment (wk) No. of 
mice 
Oc 6" 12 0 6 12 0 6 12 bledat 
12 
weeks a*-G lo bu I i ns (mg/m I) B-G lo bu I i ns (mg/m I) y-G I o bu I i ns ( mg/m I) 
6.8 8.0 7.6 5.3 5.4 6.5 3.3 4.4 4.6 9 
6.0 11.0 7.6 5.5 5.6 5.1 3.4 5.4 6.4 5 
5.0 13.6 11.3 5.3 9.4 9.0 2.7 3.6 5.1 10 
5.5 14.4 11.8 5.1 10.4 8.4 2.7 3.3 4.7 10 
6.7 13.3 10.4 5.5 9.1 7.2 3.0 9.7 11.6 1 
5.6 8.2 10.7 5.5 5.3 6.4 3.6 4.9 9.9 3 
5.9 9.1 8.0 4.9 5.5 5.4 2.3 5.4 8.0 6 
7.3 7.9 ND 5.7 5.1 ND 4.0 5.4 ND 
ND 7.2 8.9 ND 5.2 7.2 ND 5.8 7.4 9 
ND 8.2 10.2 ND 5.4 7.8 ND 5.5 6.8 12 
"All animals in each treatment group were tested at  Oand 6 weeks. 
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mammalian tissue substrate in the immuno- 
fluorescent test for ANA. Direct application of 
these substances to white cells and thyroid fol- 
lowed by incubation, washing and addition of 
fluorescein-con,jugated antimouse y-globulin 
did not produce positive tests for ANA. 
Serum Proteins 
T h e  effects of mestranol, estradiol and 
oophorectomy on serum protein concentrations 
were also studied in these animals. Serum al- 
bumin and a,-globulin levels were not changed 
after hormone administration or ovarian abla- 
tion. Mean values for serum az-, (3- and y- 
globulins are listed in Table 3. After 6 weeks of 
mestranol therapy, a,-globulins increased sig- 
nificantly in females ( P  < 0.001) and in males 
(P < 0.025) over values in female and male 
controls. Increases of aZ-globulins in mestranol- 
treated mice were sustained at significant levels 
after 12 weeks (females: P < 0.010; males: 
P < 0.001). Beta-globulin levels in mice of 
both sexes increased during mestranol treat- 
ment. These elevations represented highly sig- 
nificant increases over @-globulin levels in con- 
trols at 6 weeks (females: P < 0.001; males: 
P <  0.001)  a n d  at 1 2  weeks ( f ema les :  
P < 0.010; males: P < 0.001). After 6 weeks 
of treatment with mestranol, both female and 
male mice demonstrated an increase in serum 
7-globulin levels compared to pretreatment 
values. However, this blunted response was 
significantly different from the age-dependent 
elevation of 7-globulins found in controls after 6 
weeks (females: P < 0.005; males: P < 0.001). 
Gamma-globulins in 16- to 18-week-old mes- 
tranol-treated males at 12 weeks of treatment 
remained significantly lower than controls 
The  response to mestranol differed from that 
observed during treatment with 17-@-estradiol. 
After 6 weeks of treatment with 17-@-estradiol, 
female mice showed two distinct patterns of 
serum globulin response and were grouped ac- 
cording to this response (2). In 10 of 23 females 
(Group I), the administration of estradiol for 6 
(P  < 0.001). 
weeks resulted in significant increases of serum 
globulins over control values. Serum globulin 
levels were not increased in the remaining 13 
(Croup 2) females or in treated males. After 6 
weeks of therapy, differences in aZ-, @- and y- 
globulins between Group 1 and Group 2 fe- 
males were significant; az-, (P  < 0.050), (3-, 
( P  < 0.050) and 7-globulins, ( P  < 0.001). The  
significance of this unique pattern of response 
has been discussed elsewhere (2). The small 
number of sera (four) from treated females 
available after 12 weeks of estradiol therapy 
precluded evaluation of long-term response of 
Group 1 or Group 2 females to estradiol 
therapy. 
Mean a,-, (3- and y-globulin levels in imma- 
ture female mice treated with oophorectomy at 
4 to 6 weeks of age are also listed in Table 3. 
These values resemble globulin levels in young 
female controls. Serum globulins in older 
oophorectomized females showed no significant 
deviations from levels measured in the sham- 
operated control group 6 to 12 weeks after 
surgery. 
Histology 
Mean numbers of glomerular lesions counted 
in 27 treated and 22 control NZB/NZW mice 
are listed in Table 4. The  administration of 
mestranol or 17-@-estradiol failed to influence 
the number of glomerular lesions in 10 females 
between 4 and 30 weeks of age. There was no 
evidence in this study that the administration of 
female hormones or oophorectomy affected the 
spontaneous evolution of renal disease in female 
NZB/NZW hybrid mice. Fewer glomerular 
lesions were found in kidneys from the 3 mes- 
tranol-treated males than were identified in 
control animals. 
No evidence of hepatic damage was found on 
microscopic examination of livers from 6 mes- 
tranol, 4 estradiol and 5 control mice killed at 
24 weeks of age. Small periportal collections of 
lymphocytes were noted in the liver from 1 un- 
treated female mouse. Infiltration of lympho- 
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Table 4. Glomerular Lesions in Control and Treated NZB/NZW Mice 
Age at Mean number 
No. of examination of lesions in 
Mice kidneys examined (wk) 20 glomeruli 
Controls 
Females 13 20-34 24 
Males 5 20-38 24 
Females 5 27-30 20 
Males 3 26-29 9 
Females 5 20-24 28 
Males’ 
Immature females 6 29-33 33 
Sham-operated controls 4 28-48 35 




“All males treated with 17-@-estradiol died before the age of 20 weeks. 
cytes in the liver was not found in any of the 
animals treated with mestranol or estradiol. 
DISCUSSION 
This study is an extension of our  investiga- 
tion into the influence of estrogenic hormones 
on the evolution of autoimmune disease in hy- 
brid New Zealand mice, evaluated by studies of 
ANA, serum proteins and renal histology. Our 
data suggest that low daily doses of mestranol 
accelerate the appearance of ANA in this ani- 
mal model of au to immune disease. M a l e  
NZB/NZW mice are expected to develop ANA 
at 4 to 6 months of age, about 2 months later 
than females (1 3). McGiven and Ghose (1 4) 
surveyed 59 samples of serum from NZB/ 
NZW males, aged 1 to 6 months, for ANA and 
these sera were negative. In their experience, 
AN/\ were first detected in hybrid males at 7 
months of age. Therefore, the early appearance 
of ANA in mestranol-treated N Z B / N Z W  
males was unexpected. Unfortunately, the high 
death rate in mestranol-treated mice prevented 
a long-term study of the course of disease in 
these animals after 20 weeks of age. The  mech- 
anism of stimulation of autoantibody pro- 
duction and the predilection of treated males to 
develop ANA remains unexplained. Studies of 
differences in hormone metabolism between 
female and male NZB/NZW mice may clarify 
the apparent sex-determined responses of these 
animals to individual female hormones. 
The  apparent stimulation of ANA produc- 
tion by mestranol in NZB/NZW mice has an 
analogue in human experience. Synthetic es- 
trogen-progestogen compounds have been re- 
ported to produce serologic abnormalities in 
certain patients with incipient rheumatic 
disease (1 5). Kay et aL(4)  reported four normal 
women who developed ANA while taking oral 
contraceptives containing at least 80 r g  of mes- 
tranol per tablet. Estrogenic hormones may also 
alter immune reactions in rodents. Nicol and 
his co-workers (1 6) have shown that diethyl- 
stilbestrol stimulates activity of the reticuloen- 
dothelial system and prolongs survival time af- 
ter bacterial infection. 
Comparison of the synthetic hormone mes- 
tranol with 17-@-estradiol and oophorectomy in 
NZB/NZW mice has shown important differ- 
ences in effects on ANA and serum proteins. 
Divergent biologic responses may be produced 
by steroid hormones which are similar in struc- 
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ture. Mestranol exerts a weak estrogenic action 
on vaginal epithelium in comparison with 
natural estrogens (17) such as 17-P-estradiol. 
This study suggests that these two hormones 
may also differ in their effects on immunocom- 
petent cells. 
Other workers (1 4) have described homo- 
geneous, “membranous”  (per iphera l )  and  
speckled patterns produced on rat liver, human 
thyroid and dried human blood films when 
using sera from untreated NZB/NZW mice. 
However, the incidence of each type of im- 
munofluorescent staining in these animals was 
not reported. In the present study, sera from 
mestranol-treated males produced significantly 
more peripheral patterns than sera from con- 
trol females. Although the significance of pat- 
terns of nuclear immunofluorescence has not 
been established (1 8), some investigators have 
suggested that a “shaggy” (peripheral) pat- 
tern (6) is produced by antibodies to DNA. In 
our study, examination of kidneys from treated 
and control animals showed no evidence that 
mestranol therapy and subsequent induction of 
ANA formation accelerated the development of 
autoimmune nephritis in these NZB/NZW 
mice. Based upon current theories of the im- 
mune pathogenesis of NZB/NZW nephri- 
tis ( lo),  it would be anticipated that the ANA 
induced by mestranol are not of anti-DNA 
type. This question is currently under investi- 
gation. Unlike other examples of drug-induced 
production of autoantibodies to nuclear constit- 
uents (20), mestranol-induced ANA may fail to 
participate in immune complex formation. For 
example, ANA of the IgM class do not fix 
complement; and these autoantibodies may be 
innocuous (21). Male mice treated with a syn- 
thetic estrogenic hormone develop low levels of 
serum complement (22). Pathogenic antigen- 
antibody-complement complex formation may 
be retarded in such animals. On  the other hand, 
ANA were first detected in the sera of treated 
male mice 5 to 22 weeks before death. If long- 
term mestranol treatment were possible, per- 
sistence of autoantibodies in the sera of treated 
mice might have caused severe renal damage. 
T h e  failure of estradiol administration or 
ovarian ablation to alter the progress of disease 
in NZB/NZW mice suggests that a simple ex- 
cess or deficiency of natural estrogens does not 
play a determinate role in the evolution of au- 
toimmune nephritis in this animal genetically 
predisposed to form pathogenic immune com- 
plexes. 
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